R788 (Fostamatinib) Disodium是活性代谢产物R406的前体药物,是一种Syk抑制剂,IC50为41 nM,强效抑制Syk但不抑制Lyn,对Flt3作用效果弱5倍。
R788 (Fostamatinib) disodium, a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.
~10 μM
80 mg/kg/day分3种剂量每个3小时腹腔注射
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Braselmann S, et al. J Pharmacol Exp Ther, 2006, 319(3), 998-1008.
[2] Suljagic, M., et al., The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood, 2010. 116(23): p. 4894-905.
分子式 C23H24FN6O9PNa2 |
分子量 624.42 |
CAS号 1025687-58-4 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 5 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT02077192 | Immune Thrombocytopenic Purpura | Drug: Fostamatinib Disodium | Rigel Pharmaceuticals | Phase 3 | 2014-07-01 | 2017-03-16 |
NCT00706342 | Purpura, Thrombocytopenic, Idiopathic | Drug: Fostamatinib Disodium / R935788 | Rigel Pharmaceuticals | Phase 2 | 2007-01-01 | 2016-05-03 |
NCT02433236 | IGA Nephropathy | Drug: Fostamatinib Disodium tablet 100 mg|Drug: Fostamatinib Disodium tablet 150 mg | Rigel Pharmaceuticals | Phase 2 | 2015-09-01 | 2015-10-21 |
NCT02076412 | Immune Thrombocytopenic Purpura | Drug: Fostamatinib Disodium 100mg|Drug: Placebo|Drug: Fostamatinib Disodium 150mg | Rigel Pharmaceuticals | Phase 3 | 2014-11-01 | 2016-11-15 |
NCT02076399 | Immune Thrombocytopenic Purpura | Drug: Fostamatinib Disodium 100mg|Drug: Placebo|Drug: Fostamatinib Disodium 150mg | Rigel Pharmaceuticals | Phase 3 | 2014-05-01 | 2016-07-29 |
NCT00752999 | Systemic Lupus Erythematosus | Drug: Fostamatinib Disodium (R935788)|Drug: Placebo | Rigel Pharmaceuticals | Phase 2 | 2008-11-01 | 2012-04-26 |
NCT00665925 | Rheumatoid Arthritis | Drug: Fostamatinib disodium (R935788)|Drug: Fostamatinib disodium (R935788)|Drug: Placebo | Rigel Pharmaceuticals | Phase 2 | 2008-05-01 | 2016-08-05 |
NCT02612558 | Warm Antibody Autoimmune Hemolytic Anemia | Drug: Fostamatinib 150 mg bid | Rigel Pharmaceuticals | Phase 2 | 2016-04-01 | 2017-03-16 |
NCT00665626 | Rheumatoid Arthritis | Drug: Fostamatinib disodium (R935788)|Drug: Placebo | Rigel Pharmaceuticals | Phase 2 | 2008-05-01 | 2016-08-05 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们